Treatment of bleeding in patients with platelet disorders: Is there a place for recombinant factor VIIa?

Pathophysiology of Haemostasis and Thrombosis

Volumn 32, Issue SUPPL. 1, 2002, Pages 37-40

  Laurian, Yves ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Bleeding; Glanzmann thrombasthenia; Inherited thrombocytopathia; rFVIIa; Thrombocytopenia

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

BLEEDING; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; EX VIVO STUDY; GLANZMANN DISEASE; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; THROMBOCYTE ANOMALY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPATHY; THROMBOCYTOPENIA; BERNARD SOULIER DISEASE; REVIEW; THROMBOCYTE DISORDER;

BERNARD-SOULIER SYNDROME; BLOOD PLATELET DISORDERS; FACTOR VII; HEMORRHAGE; HUMANS; RECOMBINANT PROTEINS; THROMBASTHENIA; THROMBOCYTOPENIA;

EID: 19044370248     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057300     Document Type: Conference Paper

References (32)

1. Hedner U: NovoSeven® as a universal hemostatic agent. Blood Coagul Fibrinolysis 2000; 11(suppl 1):S107-S111.
2. Shapiro A, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA: Prospective, randomised trial of two doses of rFVIIa (Novoseven) in haemophilia patients with inhibitors undergoing Surgery. Thromb Haemost 1998;80:773-778.
3. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E: Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80:912-918.
4. Hay CRM, Negrier C, Ludlam CA: The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicentre study. Thromb Haemost 1997;78:1463-1467.
5. Poon M.C: Use of recombinant factor VIIa in hereditary bleeding disorders. Curr Opin Hematol 2001;8:312-318.
6. Roberts HR: Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul Fibrinolysis 1998;9(suppl 1):S115-S118.
7. Aledort LM: Recombinant factor VIIa is a panhemostatic agent. Thromb Haemost 2000;83: 637-638.
8. Lusher JM: Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul Fibrinolysis 2000;11(suppl 1):S45-S48.
9. Lusher JM: Recombinant activated factor VII for treatment of intramuscular haemorrhages: A comparison of early versus late treatment. Blood Coagul Fibrinolysis 1998;9(suppl 1): S111-S114.
10. Monroe DM, Hoffman M, Oliver JA, Roberts HR: Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997;99:542-547.
11. Hoffmann M, Monroe DM, Roberts HR: Activated factor VII activates factors IX and X on the surface of activated platelets: Thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998;9 (suppl 1):S61-S65.
12. Hoffman M, Monroe DM: A cell-based model of hemostasis. Thromb Haemost 2001;85:958-965.
13. Kjalke M, Ezban M, Monroe DM, Hoffmann M, Roberts HR, Hedner U: High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001;114:114-120.
14. Galan M, Reverter JC, Pino M, Vinas M, Lozano M, Ordinas A, Escolar G: Increased local procoagulant action: A mechanism contributing to the favourable hemostatic effect of activated recombinant factor VII (rFVIIa) in quanti- and qualitative disorders of platelet function. XVIII Congress of the International Society of Thrombosis and Haemostasis, Paris, France, 6-12 July 2001 (abstract).
15. Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U: Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996;26(suppl 1):159-164.
16. Tengborn L, Petruson B: A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VII. Thromb Haemost 1996;75:981-982.
17. Vidarsson B, Önundarson PT: Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 2000;83:634-635.
18. Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, Harvey D: Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplantation 2001;28:405-407.
19. Poon M-C, Demers C, Jobin F, Wu JWY: Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999;94:3951-3953.
20. d'Oiron R, Ménait C, Trzeciak C, Nurden P, Fressinaud E, Dreyfus M, Laurian Y, Négrier C: Use of rccombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost 2000;83:644-647.
21. Wielenga JJ, Siebel Y, van Buuren HR, Berends FJ, Schipperus MER, van Vliet HDDM, Kappers MC: Use of recombinant factor VIIa and HLA matched platelets to prevent bleeding during and after major surgery in a patient with Glanzmann thromboasthenia. Haemophilia 1998;4: XXIIIth Congress of the World Federation of Hemophilia (abstract).
22. Patel RK, Savidge GF, Rangarajan S: Use of recombinant factor VIIa for post-operative haemorrhage in a patient with Glanzmann's thrombasthenia and human leucocyte antigen antibodies. Br J Haematol 2001;114:245-246.
23. Ancliff P, Liesner R, Khair K, Hann I: The use of recombinant factor VIIa in a patient with severe Glanzmann's thrombasthenia to facilitate insertion of a Port-a-Cath®. Blood Coagul Fibrinolysis 1999;10:447-448.
24. Chuansumrit A, Sangkapreecha C, Hathirat P: Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa. Thromb Haemost 1999;82:1178.
25. Musso R, Cultrera D, Russo M, Giuffrida G, Venturino L, Ferlito C, Salerni S, Azzaro MP, Incatasciato D: Recombinant activated factor VII as haemostatic agent in Glanzmann's thromboastenia. Thromb Haemost 1999 (suppl), XVIIth Congress of the International Society on Thrombosis and Haemostasis (abstract).
26. Poon MC, d'Oiron R & the International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group Recombinant activated factor VII (Novoseven®) in the treatment of platelet-related bleeding disorders. Blood Coagul Fibrinolysis 2000;11(suppl 1): S55-S68.
27. Poon MC, Katsarou O, Huth-Kuehne A, Petrini P, Hann I, Demers C, Fressinaud E, Tengborn L, Thomas A, Nohe N, Strauss G, Négrier C, Makris PE, Molho P, Pautard B, Berger C, Beurrier P, Wilde J, Devecioglu O, Peters M, d'Oiron R: Recombinant factor VIIa in congenital platelet bleeding disorders American Society of Hematology 2000, 1-5 December, San Francisco. Blood; 96(suppl 1):256a (abstract).
28. Peters M, Heijboer H: Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost 1998;80:352.
29. Fressinaud E, Sigaud-Fiks M, Le Boterff C, Piot B: Use of recombinant factor VIIa (NovoSeven®) for dental extraction in a patient affected by platelet-type (pseudo-) von Willebrand disease. Haemophilia 1998;4: XXIIIth Congress of the World Federation of Hemophilia (abstract).
30. Revesz T, Arets B, Bierings M, van den Bos C, Duval E: Recombinant factor VIIa in severe uremic bleeding. Thromb Haemost 1998;80: 353.
31. Moisescu E, Ardelean L, Simion I, Muresan A, Ciupan R: Recombinant factor VIIa treatment of bleeding associated with acute renal failure. Blood Coagul Fibrinolysis 2000;11:575-577.
32. Meijer K, Sieders E, Slooff JH, de Wolf JTM, van der Meer J: Effective treatment of severe bleeding due to acquired thrombocytopathia by single dose administration of activated recombinant factor VII. Thromb Haemost 1998; 80:204-205.